Skip to content

Bicara Therapeutics BCAX Interest Income

Interest Income at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$2.79M+17.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$3.56M-50.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$7.87M+4.4%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$7.19M-41.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$2.69M-27.3%

Segments

By segment

See full
Reportable Segment$4.08M-18.6%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's interest income?
Bicara Therapeutics (BCAX) reported interest income of $4.08M in Q1 2026.
How has Bicara Therapeutics's interest income changed year-over-year?
Bicara Therapeutics's interest income decreased by 18.6% year-over-year, from $5.01M to $4.08M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.